# Rita Chiari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6056108/publications.pdf

Version: 2024-02-01

| 126 | 7,285 | 94433 37 | 71685 76 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 129 | 129 | 129 | 8542 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study. Tumori, 2022, 108, 250-257. | 1.1 | 9 |
| 2 | Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunology, Immunotherapy, 2022, 71, 865-874. | 4.2 | 11 |
| 3 | First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist, 2022, 27, 87-e115. | 3.7 | 25 |
| 4 | High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. Journal of Hematology and Oncology, 2022, 15, 9. | 17.0 | 5 |
| 5 | ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Nonâ€“Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clinical Cancer Research, 2022, 28, 2506-2516. | 7.0 | 19 |
| 6 | The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2022, 169, 103567. | 4.4 | 26 |
| 7 | Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020â€“Sep 2020; Sep 2020â€“May 2021) in the Veneto Oncology Network: The ROVID study. European Journal of Cancer, 2022, 167, 81-91. | 2.8 | 3 |
| 8 | Host immuneâ€inflammatory markers to unravel the heterogeneous outcome and assessment of patients with <scp>PDâ€L1</scp> â‰¥50% metastatic nonâ€small cell lung cancer and poor performance status receiving firstâ€line immunotherapy. Thoracic Cancer, 2022, 13, 483-488. | 1.9 | 7 |
| 9 | Exploring metastatic breast cancer treatment changes during COVID-19 pandemic. Journal of Chemotherapy, 2021, 33, 263-268. | 1.5 | 7 |
| 10 | Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28. | 2.8 | 81 |
| 11 | Antibodyâ€“drug conjugates for lung cancer in the era of personalized oncology. Seminars in Cancer Biology, 2021, 69, 268-278. | 9.6 | 17 |
| 12 | Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports, 2021, 2, 100114. | 1.1 | 11 |
| 13 | Smoking status during firstâ€line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A caseâ€“control matched analysis from a large multicenter study. Thoracic Cancer, 2021, 12, 880-889. | 1.9 | 30 |
| 14 | High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. Genes, 2021, 12, 273. | 2.4 | 14 |
| 15 | The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. Journal of Clinical Medicine, 2021, 10, 1005. | 2.4 | 23 |
| 16 | Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2021, 39, 723-733. | 1.6 | 329 |
| 17 | Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study. European Journal of Cancer, 2021, 147, 120-127. | 2.8 | 15 |
| 18 | Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421. | | 80 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 4403. | 4.1 | 24 |
| 20 | Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiologia Medica, 2021, 126, 1117-1128. | 7.7 | 18 |
| 21 | Post-progression outcomes of NSCLC patients with PD-L1 expression â‰¥ 50% receiving first-line single-agent pembrolizumab in a large multicentreÂreal-world study. European Journal of Cancer, 2021, 148, 24-35. | 2.8 | 19 |
| 22 | Predictive ability of a drug-based score in patients with advanced nonâ€“small-cell lung cancer receiving first-line immunotherapy. European Journal of Cancer, 2021, 150, 224-231. | 2.8 | 24 |
| 23 | Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. Oncologist, 2021, 26, e1854-e1861. | 3.7 | 16 |
| 24 | PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. Journal of Translational Medicine, 2021, 19, 270. | 4.4 | 14 |
| 25 | Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. Genes, 2021, 12, 992. | 2.4 | 5 |
| 26 | The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2021, 165, 103436. | 4.4 | 40 |
| 27 | Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. Radiologia Medica, 2020, 125, 214-219. | 7.7 | 10 |
| 28 | ROS1-rearranged Nonâ€“small-cell Lung Cancer isÂAssociated With a High Rate of VenousÂThromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms TrialÂ(METROS). Clinical Lung Cancer, 2020, 21, 15-20. | 2.6 | 58 |
| 29 | Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Lung Cancer, 2020, 140, 71-79. | 2.0 | 8 |
| 30 | Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression â‰¥ 50%: a multicenter study with external validation. , 2020, 8, e001403. | | 57 |
| 31 | Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361. | | 126 |
| 32 | Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. European Journal of Cancer, 2020, 140, 140-146. | 2.8 | 18 |
| 33 | Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of â‰¥â€‰50%. Cancer Immunology, Immunotherapy, 2020, 69, 2209-2221. | 4.2 | 60 |
| 34 | Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool. Frontiers in Immunology, 2020, 11, 839. | 4.8 | 28 |
| 35 | Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 ExpressionÂâ‰¥ 50% and Their Relationship With Clinical Outcomes. Clinical Lung Cancer, 2020, 21, 498-508.e2. | 2.6 | 50 |
| 36 | Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunology, Immunotherapy, 2020, 69, 1177-1187. | 4.2 | 66 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26. | 2.8 | 85 |
| 38 | Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. Journal of Clinical Medicine, 2020, 9, 1047. | 2.4 | 47 |
| 39 | Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Nonâ€“small-cell Lung Cancer Progressing on Crizotinib. Clinical Lung Cancer, 2020, 21, e478-e487. | 2.6 | 2 |
| 40 | Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. , 2020, 69, 1177. | | 1 |
| 41 | Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28. | 2.8 | 45 |
| 42 | Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. Anticancer Research, 2019, 39, 4265-4271. | 1.1 | 33 |
| 43 | Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. Lung Cancer, 2019, 134, 210-217. | 2.0 | 12 |
| 44 | Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987772. | 3.2 | 16 |
| 45 | Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lung Cancer, 2019, 138, 79-87. | 2.0 | 29 |
| 46 | Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1â€“2 trial. Lancet Oncology, The, 2019, 20, 1691-1701. | 10.7 | 233 |
| 47 | Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report. In Vivo, 2019, 33, 2021-2026. | 1.3 | 3 |
| 48 | Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Nonâ€“Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clinical Cancer Research, 2019, 25, 7312-7319. | 7.0 | 139 |
| 49 | Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. Cancers, 2019, 11, 1431. | 3.7 | 7 |
| 50 | Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2019, 8, 131. | 2.4 | 42 |
| 51 | Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. Journal of Clinical Oncology, 2019, 37, 2738-2745. | 1.6 | 138 |
| 52 | Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337. | 3.7 | 131 |
| 53 | Texture Analysis on [18F]FDG PET/CT in Non-Small-Cell Lung Cancer: Correlations Between PET Features, CT Features, and Histological Types. Molecular Imaging and Biology, 2019, 21, 1200-1209. | 2.6 | 53 |
| 54 | A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57. | | 275 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2019, 37, 1370-1379. | 1.6 | 282 |
| 56 | Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer, 2019, 20, 237-247.e1. | 2.6 | 118 |
| 57 | Safety and Efficacy of Nivolumab in Patients With Advanced Nonâ€“small-cell Lung Cancer Treated Beyond Progression. Clinical Lung Cancer, 2019, 20, 178-185.e2. | 2.6 | 35 |
| 58 | Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. , 2019, 7, 316. | | 102 |
| 59 | A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics. Journal of Thoracic Oncology, 2019, 14, 130-134. | 1.1 | 92 |
| 60 | Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 159-168. | 2.8 | 27 |
| 61 | Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. British Journal of Cancer, 2019, 120, 57-62. | 6.4 | 68 |
| 62 | Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. Clinical Lung Cancer, 2019, 20, e186-e194. | 2.6 | 40 |
| 63 | Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. , 2019, 196, 105-116. | | 88 |
| 64 | Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 479-485. | 2.5 | 253 |
| 65 | Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Future Oncology, 2018, 14, 353-361. | 2.4 | 3 |
| 66 | Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. Medical Oncology, 2018, 35, 72. | 2.5 | 29 |
| 67 | Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. Lung Cancer, 2018, 120, 70-74. | 2.0 | 5 |
| 68 | Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma. Journal of Thoracic Oncology, 2018, 13, e9-e12. | 1.1 | 8 |
| 69 | Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. International Journal of Biological Markers, 2018, 33, 549-550. | 1.8 | 0 |
| 70 | Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: AÂModel From Lung Cancer. Clinical Lung Cancer, 2018, 19, 191-198. | 2.6 | 5 |
| 71 | Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. Medical Oncology, 2018, 35, 4. | 2.5 | 17 |
| 72 | Fatal acute disseminated intravascular coagulation as presentation of advanced ALK -positive non-small cell lung cancer: Does oncogene addiction matter?. Thrombosis Research, 2018, 163, 51-53. | 1.7 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC. Translational Lung Cancer Research, 2018, 7, S127-S130. | 2.8 | 2 |
| 74 | Early stage resectable non-small cell lung cancer: is neoadjuvant immunotherapy the right way forward?. Journal of Thoracic Disease, 2018, 10, S3890-S3894. | 1.4 | 9 |
| 75 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncology, The, 2018, 19, 1654-1667. | 10.7 | 587 |
| 76 | Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661880865. | 2.6 | 22 |
| 77 | KRAS mutation and DNA repair and synthesis genes in nonâ€'smallâ€'cell lung cancer. Molecular and Clinical Oncology, 2018, 9, 689-696. | 1.0 | 7 |
| 78 | Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib. Journal of Thoracic Oncology, 2018, 13, e220-e222. | 1.1 | 5 |
| 79 | Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. Clinical Drug Investigation, 2018, 38, 983-987. | 2.2 | 14 |
| 80 | Italian Nivolumab Expanded Access Program inÂNonsquamous Nonâ€"Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. Journal of Thoracic Oncology, 2018, 13, 1146-1155. | 1.1 | 77 |
| 81 | Sensitivity and specificity of breast cancer ICD-9-CM codes in three Italian administrative healthcare databases: a diagnostic accuracy study. BMJ Open, 2018, 8, e020627. | 1.9 | 11 |
| 82 | Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation. Journal of Thoracic Oncology, 2018, 13, e145-e147. | 1.1 | 15 |
| 83 | Osimertinib. Recent Results in Cancer Research, 2018, 211, 257-276. | 1.8 | 24 |
| 84 | Accuracy of lung cancer ICD-9-CM codes in Umbria, Napoli 3 Sud and Friuli Venezia Giulia administrative healthcare databases: a diagnostic accuracy study. BMJ Open, 2018, 8, e020628. | 1.9 | 9 |
| 85 | First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, The, 2017, 389, 917-929. | 13.7 | 919 |
| 86 | Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology, 2017, 35, 1281-1287. | 1.6 | 126 |
| 87 | Optimal management of ALK -positive NSCLC progressing on crizotinib. Lung Cancer, 2017, 106, 58-66. | 2.0 | 33 |
| 88 | Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. Medical Oncology, 2017, 34, 105. | 2.5 | 47 |
| 89 | Long-Lasting Response toÂNivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Nonâ€"Small Cell Lung Cancer Patient. Journal of Thoracic Oncology, 2017, 12, e51-e55. | 1.1 | 3 |
| 90 | The safety of nivolumab for the treatment of advanced non-small cell lung cancer. Expert Opinion on Drug Safety, 2017, 16, 101-109. | 2.4 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 387-404. | 3.2 | 30 |
| 92 | Large Cell Neuroendocrine Carcinoma Transformation and EGFR -T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. Mayo Clinic Proceedings, 2017, 92, 1304-1311. | 3.0 | 24 |
| 93 | Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?. Journal of Radiation Oncology, 2017, 6, 11-19. | 0.7 | 1 |
| 94 | Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2017, 23, 2195-2202. | 7.0 | 208 |
| 95 | Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study. Oncotarget, 2017, 8, 83343-83353. | 1.8 | 6 |
| 96 | Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. Journal of Breast Cancer, 2016, 19, 324. | 1.9 | 14 |
| 97 | Validity of ICD-9-CM codes for breast, lung and colorectal cancers in three Italian administrative healthcare databases: a diagnostic accuracy study protocol: TableÂ1. BMJ Open, 2016, 6, e010547. | 1.9 | 17 |
| 98 | Malignant Giant Solitary Fibrous Tumor of the Pleura Metastatic to the Thyroid Gland. Tumori, 2016, 102, S16-S21. | 1.1 | 6 |
| 99 | Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2016, 99, 31-37. | 2.0 | 31 |
| 100 | Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 2016, 95, 82-87. | 2.0 | 19 |
| 101 | Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-NaÃ¯ve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer. Clinical Drug Investigation, 2016, 36, 683-686. | 2.2 | 27 |
| 102 | How might treatment of ALK-positive non-small cell lung cancer change in the near future?. Expert Review of Anticancer Therapy, 2016, 16, 997-999. | 2.4 | 2 |
| 103 | Alectinibâ€™s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. Journal of Neuro-Oncology, 2016, 129, 355-361. | 2.9 | 25 |
| 104 | Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. Medical Oncology, 2016, 33, 18. | 2.5 | 129 |
| 105 | Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis. Oncotarget, 2016, 7, 30561-30574. | 1.8 | 37 |
| 106 | Preface on â€œEmerging treatment options for brain metastases from non-small cell lung cancerâ€: Translational Lung Cancer Research, 2016, 5, 561-562. | 2.8 | 1 |
| 107 | CSF Concentration of Crizotinib in Two ALK-Positive Nonâ€“Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment. Journal of Thoracic Oncology, 2015, 10, e26-e27. | 1.1 | 93 |
| 108 | miRNAs and resistance to EGFRâ€”TKIs in EGFR-mutant non-small cell lung cancer: beyond â€˜traditional mechanismsâ€™ of resistance. Ecancermedicalscience, 2015, 9, 569. | 1.1 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Bronchiolitis Obliterans Organizing Pneumonia after Radiation Therapy for Lung Cancer: A Case Report. Tumori, 2015, 101, e88-e91. | 1.1 | 4 |
| 110 | Future options for ALK-positive non-small cell lung cancer. Lung Cancer, 2015, 87, 211-219. | 2.0 | 50 |
| 111 | c-Met targeting in advanced gastric cancer: An open challenge. Cancer Letters, 2015, 365, 30-36. | 7.2 | 67 |
| 112 | Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2015, 16, 2601-2613. | 1.8 | 22 |
| 113 | Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. Lung Cancer, 2015, 90, 255-260. | 2.0 | 43 |
| 114 | Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. Thrombosis Research, 2015, 136, 924-927. | 1.7 | 39 |
| 115 | Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. Journal of Thoracic Oncology, 2015, 10, 1437-1443. | 1.1 | 163 |
| 116 | Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Nonâ€“Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. Clinical Lung Cancer, 2014, 15, 86-92. | 2.6 | 40 |
| 117 | Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series. Clinical Lung Cancer, 2014, 15, 470-474. | 2.6 | 13 |
| 118 | Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2014, 15, 411-417.e4. | 2.6 | 32 |
| 119 | Long-Term Response to Gefitinib and Crizotinib in Lung Adenocarcinoma Harboring Both Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion Gene. Journal of Clinical Oncology, 2014, 32, e30-e32. | 1.6 | 38 |
| 120 | Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 663-671. | 2.8 | 6 |
| 121 | Selumetinib: a promising pharmacologic approach forKRAS-mutant advanced non-small-cell lung cancer. Future Oncology, 2013, 9, 167-177. | 2.4 | 19 |
| 122 | Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer, 2012, 78, 81-86. | 2.0 | 68 |
| 123 | Colonic metastases from non-small cell lung cancer. Revista Espanola De Enfermedades Digestivas, 2012, 104, 447-448. | 0.3 | 0 |
| 124 | Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 707-715. | 1.1 | 160 |
| 125 | Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2011, 6, 2018-2026. | 1.1 | 50 |
| 126 | Antitumor Immunity at Work in a Melanoma Patient. Advances in Cancer Research, 1999, 76, 213-242. | 5.0 | 39 |